Affiliation:
1. Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709
Abstract
The ability of a potent dihydrofolate reductase inhibitor, trimethoprim, to inhibit the growth of
Escherichia coli
B in vitro is dependent on the composition of the medium in which the cells are grown. The inhibition observed in minimal broth could be partially reversed by the addition of thymidine, ribonucleosides, amino acids, and vitamins. No reversal occurred in the absence of thymidine. In a number of commercially prepared media, the inhibitory activity of trimethoprim correlated inversely with the amount of thymidine found to be present by microbiological assay. The significance of these findings for the routine testing of new, synthetic antibacterial agents is discussed.
Publisher
American Society for Microbiology
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference18 articles.
1. A suggested mechanism for the selective procedure for isolating thymine-requiring mutants of Escherichia coli;Bertino J. B.;Biochem. J.,1966
2. Inhibitor binding analysis of dihydrofolate reductases from various species;Burchall J. J.;Mol. Pharmacol.,1965
3. Trimethoprim, a sulphonamide potentiator;Bushby S. R. M.;Brit. J. Pharmacol.,1968
4. Initiation of E. coli proteins;Capecchi M. R.;Proc. Nat. Acad. Sci. U.S.A.,1966
5. Trimethoprim: laboratory and clinical studies;Darrell J. H.;J. Clin. Pathol.,1968
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献